Valuation: RenovoRx, Inc.

Market Cap 60.02M 53.76M 49.45M 44.8M 83.75M 5.7B 85.32M 590M 237M 3B 225M 220M 9.45B P/E 2026 *
-5.12x
P/E 2027 * -9.5x
Enterprise Value 60.02M 53.76M 49.45M 44.8M 83.75M 5.7B 85.32M 590M 237M 3B 225M 220M 9.45B EV / Sales 2026 *
15.5x
EV / Sales 2027 * 5.25x
Free-Float
96.41%
Yield 2026 *
-
Yield 2027 * -
10-07 RenovoRx, Inc. Advances TAMP Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated PRISM-TAMP Trial CI
10-01 RenovoRx, Inc. Announces Peer-Reviewed Publication Highlighting TAMP? Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer CI
08-25 RenovoRx Publishes Pharmacokinetic and Pharmacodynamic Data Supporting Tamp Platform?s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer CI
08-24 RenovoRx, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-20 RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter for Targeted Therapeutic Drug-Delivery for Cancer Treatment CI
08-13 RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-13 Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 CI
08-11 RenovoRx Achieves Full Enrollment in Phase III Tiger-Pac Trial for Locally Advanced Pancreatic Cancer CI
08-06 RenovoRx Announces First Commercial Clinical Use Of RenovoCath In Sarcoma Patient Treatment CI
08-06 Renovorx Inc and Carti Cancer Center Announce First Commercial Clinical Use of Renovocath in Sarcoma Patient Treatment CI
06-23 RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, Jun-23-2026 12:30 PM
06-11 RenovoRx Announces Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP In Locally Advanced Pancreatic Cancer CI
06-02 RenovoRx, Inc., Q1 2026 Earnings Call, May 14, 2026
1 day-10.74%
1 week+3.10%
1 month-14.74%
3 months+38.79%
6 months+56.47%
Current year+58.31%
1 week 1.27
Extreme 1.27
1.52
1 month 1.09
Extreme 1.09
1.61
Current year 0.77
Extreme 0.77
2.59
1 year 0.7
Extreme 0.7006
2.59
3 years 0.53
Extreme 0.5306
2.59
5 years 0.53
Extreme 0.5306
12.51
10 years 0.53
Extreme 0.5306
16.74
Manager TitleAgeSince
Chief Executive Officer 49 27/10/2014
Chief Tech/Sci/R&D Officer 60 01/12/2009
Director of Finance/CFO 71 03/02/2026
Director TitleAgeSince
Director/Board Member 82 01/12/2012
Chairman 60 01/05/2018
Director/Board Member 84 01/01/2012
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

55,924 0.1239%
01/10/26 Free

Director

55,924 0.1239%
01/10/26 Free

Director

55,924 0.1239%
Change 5-day change 1-year change 3-year change Capi.($)
-10.74%+3.10%+19.82%+16.67% 60.02M
+1.56%+2.41%-14.09%+12.32% 184B
-0.59%+1.18%+6.44%+36.82% 118B
-6.38%-4.98%-18.07%+8.01% 111B
+3.42%+1.71%-41.92%+8.01% 94.58B
+0.09%-0.05%-2.06%+78.69% 63.13B
-0.46%+0.42%+4.48%+82.84% 55.66B
-0.23%-0.52%+10.73%-21.72% 53.9B
-4.30%-1.64%-12.44%+37.99% 43.42B
+0.58%+2.00%-1.17%-8.82% 34.68B
Average -1.70%+0.36%-4.83%+25.08% 75.85B
Weighted average by Cap. -0.49%+0.24%-10.13%+23.75%

Financials

2026 *2027 *
Net sales 3.87M 3.47M 3.19M 2.89M 5.4M 368M 5.5M 38.04M 15.27M 193M 14.53M 14.22M 610M 11.43M 10.24M 9.42M 8.53M 15.95M 1.09B 16.25M 112M 45.09M 571M 42.91M 42M 1.8B
Net income -12M -10.75M -9.89M -8.96M -16.74M -1.14B -17.06M -118M -47.33M -599M -45.04M -44.08M -1.89B -7.01M -6.28M -5.78M -5.23M -9.78M -666M -9.97M -68.89M -27.66M -350M -26.32M -25.76M -1.1B
Net Debt - -
Projected Income Statement - Annual - RenovoRx, Inc.
Logo RenovoRx, Inc.
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Employees
-
Date Price Change Volume
30/10/26 $1.330 -10.74% 376,394
29/10/26 $1.490 +4.56% 387,212
28/10/26 $1.425 +2.52% 173,143
27/10/26 $1.390 +6.11% 289,416
26/10/26 $1.310 +1.55% 182,305
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - RenovoRx, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.330USD
Average target price
7.125USD
Spread / Average Target
+435.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - RenovoRx, Inc.
  1. Stock Market
  2. Stocks
  3. RNXT Stock